Related Experiment Videos
The mitroflow pericardial valve. First results of a follow-up study
D Loisance1, M L Hillion, J P Cachera
1Department of Cardiac Surgery, C.H.U. Henri Mondor, Créteil, France.
Insights
The Mitroflow pericardial valve demonstrates infrequent early primary failure in patients. Postoperative mortality is mainly due to noncardiac complications, with minimal thromboembolic events observed.
Area of Science:
- Cardiology
- Biomaterials Science
- Surgical Innovation
Background:
- The Mitroflow pericardial valve was implanted in 166 patients between March 1983 and December 1986.
- A total of 188 valves were implanted during this period.
- Long-term follow-up data is crucial for assessing prosthetic valve performance.
Purpose of the Study:
- To evaluate the early performance and complications of the Mitroflow pericardial valve.
- To determine the rates of mortality, valve explantation, and thromboembolic events.
- To assess the incidence of prosthetic valve infection.
Main Methods:
- A retrospective analysis of 166 patients who received 188 Mitroflow pericardial valves.
- Follow-up data was collected for a total of 4316 patient-months.
- Outcomes assessed included mortality, valve explantation, thromboembolic episodes, and prosthetic infections.
Main Results:
- Early postoperative mortality (within three months) was approximately 10%, primarily linked to noncardiac complications.
- One valve explantation occurred at 22 months due to cusp tear.
- Thromboembolic episodes were minimal (six cases), with 47% of patients not on anticoagulant therapy.
- One patient required reoperation for prosthetic infection after active infective endocarditis (SBE).
Conclusions:
- Early primary failure of the Mitroflow valve is infrequent.
- The valve demonstrates a low rate of thromboembolic complications.
- Noncardiac complications represent a significant factor in early postoperative mortality.
Abstract:
One hundred eighty-eight Mitroflow pericardial valves, implanted on 166 patients from March 1983 to December 1986, have been followed for a total of 4316 patients x months. Mortality rate in the first three postoperative months is approximately 10% related to noncardiac complications. One hundred forty-nine patients are living at the start of the follow up period. During that period, one valve was explanted after 22 months for a cusp tear. The rate of thrombo embolic episode is minimal, six cases, as 47% are free of any anticoagulant therapy. One patient, operated upon for active SBE, required additional surgery 2 months later for a prosthetic infection. The present results suggest that early primary failure of Mitroflow valve is quite unfrequent.